secwatch.observer — SEC 8-K summary
======================================

Issuer:     RIGEL PHARMACEUTICALS INC (RIGL)
CIK:        0001034842
Form:       8-K
Filed at:   2025-03-10T23:59:59+00:00
Accession:  0001104659-25-022224
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Rigel Pharmaceuticals appoints Mark J. Frohlich to board of directors
---------------------------------------------------------------------

- Appointed March 6, 2025; joins class of directors with term expiring at 2027 annual meeting.
- Will serve on Corporate Governance, Health Care Compliance Oversight and Nominating Committee and Scientific and Clinical Trial Advisory Committee.
- Received initial option grant for 12,000 shares; annual retainer $50,000 plus $10,000 per committee.
- Board determined Frohlich is independent under SEC and Nasdaq standards; no familial relationships.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1034842/000110465925022224/0001104659-25-022224-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1034842/000110465925022224/tm258676d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-022224

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer